article thumbnail

eBook: HR Development within the Life Sciences Industry

XTalks

Disruption is very commonly witnessed in the life sciences industry hence human resources (HR) departments need to continuously come up with new talent strategies and recruitment practices to stay progressive. . Are you looking to understand the powerful impact HR has on the overall success of the global life science industry?

HR 89
article thumbnail

FDA grants approval to Gilead Sciences’ breast cancer therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Trodelvy (sacituzumab govitecan-hziy) to treat unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer adult patients. Trodelvy showed 3.2

HR 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Pharma Mirror

The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific

HR 130
article thumbnail

Itovebi (Inavolisib) Gains FDA Nod for PIK3CA-Mutated HR-Positive, HER2-Negative Breast Cancer

XTalks

The US Food and Drug Administration (FDA) has approved Itovebi (inavolisib) for the treatment of adults with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation. Why Target PIK3CA Mutations?

HR 95
article thumbnail

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

The regulatory approval was based on the data obtained from the DESTINY-Breast04 Phase III trial, which was conducted in HR-positive or HR-negative, HER2-low unresectable or metastatic breast cancer patients, who have received one or two prior lines of chemotherapy.

HR 321
article thumbnail

SABCS: Pharmas show their working in HR+/HER2- breast cancer

pharmaphorum

There was also new data from the monarchE trial of Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) in combination with endocrine therapy as an adjuvant treatment for patients with high risk, early-stage HR+/HER2- breast cancer. The post SABCS: Pharmas show their working in HR+/HER2- breast cancer appeared first on.

HR 98
article thumbnail

LEAP HR: Life Sciences West

pharmaphorum

Join us in San Francisco, CA this April for LEAP HR: Life Sciences West to network with 200+ senior HR leaders

HR 52